Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this retrospective study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeiner, Pia S., Kinzig, Martina, Divé, Iris, Maurer, Gabriele D., Filipski, Katharina, Harter, Patrick N., Senft, Christian, Bähr, Oliver, Hattingen, Elke, Steinbach, Joachim P., Sörgel, Fritz, Voss, Martin, Steidl, Eike, Ronellenfitsch, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947028/
https://www.ncbi.nlm.nih.gov/pubmed/31766326
http://dx.doi.org/10.3390/jcm8122031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947028/
https://www.ncbi.nlm.nih.gov/pubmed/31766326
http://dx.doi.org/10.3390/jcm8122031

Ejemplares similares